Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
Lesley A. Ward, Dennis S.W. Lee, Anshu Sharma, Angela Wang, Ikbel Naouar, Xianjie I. Ma, Natalia Pikor, Barbara Nuesslein-Hildesheim, Valeria Ramaglia, Jennifer L. Gommerman
Lesley A. Ward, Dennis S.W. Lee, Anshu Sharma, Angela Wang, Ikbel Naouar, Xianjie I. Ma, Natalia Pikor, Barbara Nuesslein-Hildesheim, Valeria Ramaglia, Jennifer L. Gommerman
View: Text | PDF
Research Article Immunology

Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury

  • Text
  • PDF
Abstract

Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease progression. Although the mechanism(s) that mediate pathogenesis in the subpial compartment remain unclear, it has been speculated that inflammation in the overlying meninges may be associated with subpial injury. Here we show that adoptive transfer of proteolipid protein–primed Th17 cells into SJL/J recipient mice induces subpial demyelination associated with microglial/macrophage activation, disruption of the glial limitans, and evidence of an oxidative stress response. This pathology was topologically associated with foci of immune cells in the meninges and occurred in the absence of measurable anti–myelin oligodendrocyte glycoprotein IgM or IgG antibodies. To test the role of brain-infiltrating leukocytes on subpial injury, we modulated sphingosine 1-phosphate (S1P) receptor1,5 activity with BAF312 (siponimod) treatment. Administration of BAF312, even after adoptively transferred T cells had entered the brain, significantly ameliorated clinical experimental autoimmune encephalomyelitis and diminished subpial pathology, concomitant with a selective reduction in the capacity of transferred T cells to make Th17 cytokines. We conclude that sustained subpial cortical injury is associated with the capacity for brain-resident T cells to produce Th17 cytokines, and this pathological process occurs in an S1P receptor1,5–dependent manner.

Authors

Lesley A. Ward, Dennis S.W. Lee, Anshu Sharma, Angela Wang, Ikbel Naouar, Xianjie I. Ma, Natalia Pikor, Barbara Nuesslein-Hildesheim, Valeria Ramaglia, Jennifer L. Gommerman

×

Figure 7

Therapeutic treatment with BAF312 reduces demyelination, microglia/macrophage reactivity, and glial limitans disruption in A/T SJL/J EAE mice.

Options: View larger image (or click on image) Download as PowerPoint
Therapeutic treatment with BAF312 reduces demyelination, microglia/macro...
(A–D) Immunostaining and quantitative analysis for PLP in brain sections (layers 1–3 of the somatosensory cortex) from naive mice (n = 3) and A/T SJL/J EAE mice at day 11 (acute phase) treated with either vehicle control (CMC, n = 12) or BAF312 over time (from day 3, n = 4; from day 5, n = 7). Zoomed areas show myelin changes in layer 1 of the somatosensory cortex. (E–H) Immunostaining and quantitative analysis for the Tppp/p25 marker of myelinating oligodendrocytes in brain sections from naive mice and A/T SJL/J EAE mice treated with either vehicle control or BAF312 over time, as above. Zoomed areas show Tppp/p25+ cells (arrows) in layer 2 of the somatosensory cortex. (I–L) Immunostaining and quantitative analysis for Iba1 in brain sections from naive mice and A/T SJL/J EAE mice treated with either vehicle control or BAF312 over time, as above. Zoomed areas show microglia/macrophages closely apposed to neurons in CMC-treated A/T SJL/J EAE mice (zoom J) but not in naive (zoom I) or BAF312-treated A/T SJL/J EAE mice (zoom K). (M–P) Immunostaining and quantitative analysis for GFAP in brain sections from naive mice and A/T SJL/J EAE mice treated with either vehicle control or BAF312 over time, as above. Zoomed areas show a disrupted glial limitans and enlarged GFAP+ astrocytes underlying meningeal TLT in A/T SJL/J EAE mice treated with CMC (arrows in zoom N), whereas GFAP+ astrocytes with processes that extend toward the pia mater and form an intact glial limitans were seen in naive (zoom M) and BAF312-treated mice (zoom O). For all quantifications, values are shown as mean ± SEM, and statistical analysis was done by Kruskal-Wallis with Dunn’s correction for multiple comparisons, with *P < 0.05, and **P < 0.01. M, meninges. Scale bars: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts